Adicet Bio Secures FDA Alignment for Outpatient Dosing of Prula-cel, Doubles Enrollment, and Plans Pivotal Trial
ACET is trading near its 52-week low of $7.154 (10% above the low).
Summary
Adicet Bio announced significant progress in its autoimmune disease pipeline, including FDA alignment for outpatient dosing of prula-cel, doubled patient enrollment, and plans for a pivotal Phase 2 trial in 2H 2026.
Key Events · Product Development and Regulatory · ACET
-
FDA Alignment for Outpatient Dosing
Adicet Bio reached alignment with the FDA to allow prula-cel dosing in an outpatient setting for lupus nephritis and systemic lupus erythematosus patients in ongoing and future clinical trials.
-
Prula-cel Enrollment Doubled
Enrollment in the prula-cel Phase 1 program for autoimmune diseases has more than doubled to over 20 patients as of December 31, 2025.
-
Pivotal Trial Pathway Established
The company plans to request an FDA meeting in Q2 2026 to discuss Phase 2 pivotal trial design for prula-cel, with an aim to initiate a pivotal study in 2H 2026.
-
ADI-212 Regulatory Filing Planned
Adicet Bio expects to submit a regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in the first half of 2026.
Analysis · ACET · Life Sciences
This 8-K details several positive developments that significantly advance Adicet Bio's clinical pipeline and regulatory strategy. The FDA's alignment to allow outpatient dosing for prula-cel in lupus nephritis and systemic lupus erythematosus patients is a crucial operational and patient-centric win, potentially accelerating future trial enrollment and reducing costs. Doubling patient enrollment in the Phase 1 autoimmune program further demonstrates strong clinical progress. The company's intention to meet with the FDA in Q2 2026 to discuss pivotal trial design and initiate a Phase 2 pivotal study in 2H 2026 provides a clear and accelerated path towards potential commercialization for its lead candidate. Additionally, the planned regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer in 1H 2026 highlights the advancement of its broader pipeline. These milestones collectively de-risk the company's development programs and provide a positive outlook for investors.
At the time of this filing, ACET was trading at $7.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $77.1M. The 52-week trading range was $7.15 to $17.44. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.